Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD)  by Izquierdo-Alonso, José Luis et al.
Respiratory Medicine (2013) 107, 724e731Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate /rmedPrevalence and characteristics of three
clinical phenotypes of chronic obstructive
pulmonary disease (COPD)Jose´ Luis Izquierdo-Alonso a,*,
Jose Miguel Rodriguez-Gonza´lezMoro b,
Pilar de Lucas-Ramos b, Irune Unzueta c, Xabier Ribera d,
Esther Anto´n e, Antonio Martı´n ca Pulmonology Service, University Hospital of Guadalajara, Spain
b Pulmonology Service, University General Hospital Gregorio Maran˜o´n, Madrid, Spain
cMedical Department, Pfizer, Spain
dMedical Department, Boehringer Ingelheim, Spain
e Pulmonology Service, Hospital de Mo´stoles, Madrid, Spain
Received 8 November 2012; accepted 2 January 2013
Available online 16 February 2013KEYWORDS
COPD;
Phenotype;
Clinical
characteristics* Corresponding author. Servicio de
Espan˜a, Spain. Tel.: þ34 655946652;
E-mail addresses: jlizquierdo@sesc
0954-6111/$ - see front matter ª 201
http://dx.doi.org/10.1016/j.rmed.20Summary
Aim: To determine the prevalence and analyze the most relevant clinical characteristics of
three clinical phenotypes of COPD: emphysema (type 1), chronic bronchitis (type 2) or
COPD-asthma (type 3).
Method: Observational, multicenter study performed with 331 COPD patients recruited in pul-
monology outpatient services. The stratification in three phenotypes was performed with
imaging tests, pulmonary function, and a standardized clinical questionnaire.
Results: The 43.2% presented an emphysematous phenotype, 44.7% were chronic bronchitic and
the other 12.1% presented a phenotype showing mixed characteristics with asthma. There were
no significant differences in the smoking level, in the gasometric values or time of disease evo-
lution. Type 1 patients showed lower FEV1 values in comparison with types 2 and 3, 46.6% (21.1),
55.2% (21.2) and 54.4% (21.8), respectively (p< 0.05), and greater levels of dyspnea (p< 0.05).
No significant differences were observed in the percentage of patients who had at least one
exacerbation in the last year (68.8%, 63.9%, 64.9%; pZ 0.25), in the number of exacerbations
(pZ 0.56), in the number of visits to the ER (total and due to COPD), or in the number of hospital
admittances. Type 2 patients showed a greater prevalence of cardiovascular comorbidities and
of sleep apnea syndrome (4.9%, 23.6% and 12.5%, respectively, p < 0.001).Neumologı´a, Hospital Universitario de Guadalajara, C/ Donante de sangre sn, 19002 Guadalajara,
fax: þ34 949209218.
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Clinical characteristics in COPD phenotypes 725Table 1 Inclusion and exclusion
Inclusion criteria
 Patients aged 40 or older.
 Patients with smoking backgro
 Patients diagnosed with Chron
lator FEV1/FVC (after inhaling
 Patients receiving treatment
centers.
 Clinical stability in the last m
 Patients who have given their
Exclusion criteria
 Patients with current asthma
 Patients with a primary pulmo
 Patients presenting, at the tim
make the fulfillment of the reConclusions: In COPD, emphysematous patients present worse pulmonary function and greater
dyspnea, although there were no differences in the use of hospital health care resources.
The greater comorbidity in Group 2 patients may require specific strategies in this subgroup
of patients.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
The main clinical guidelines define COPD by the presence of
chronic, almost irreversible, airflow obstruction. The main
critic that these guidelines provoke is that they ponder too
much the values of the forced spirometry in the diagnosis and
the assessment of COPD severity, thus preventing the ade-
quate assessment of the “various faces of the disease”.
Although a better approach, based on the different pheno-
types, without a doubt, increases the complexity of COPD,
the currently available information indicates that it is not
justified to continue assuming that a classification based
exclusively in spirometric criteria is a good classification.
Putting our current knowledge about COPD into per-
spective, we could say that the continuous exposure to
smoking fumes or environmental toxics causes an airflow
obstruction, but with marked differences in the inflamma-
tory response, and the damage caused in both the airway
and the pulmonary parenchyma. Such damage, in the case
of the emphysema, finally leads to destruction.
More than four decades ago, Burrows1 defined the
emphysematous phenotype so as to differentiate it from
the bronchitic phenotype. Since the initial description,
various observational studies have confirmed the existence
of a group of patients with peculiar characteristics, such as
the presence of emphysema in imaging techniques, and
a decrease in the diffusion test; they are usually patients
that tended to produce little sputum, with a lower rate of
body mass index (BMI), arterial blood gases best preserved
and greater dyspnea. On the contrary, the group with
a preponderance of chronic bronchitis usually do not show
evidence of emphysema in their chest-X rays and often
have well preserved diffusing capacities. It is not infre-
quent to find exacerbations of this disease associated tocriteria.
und whose pack-year index (PY
ic Obstructive Pulmonary Disea
400 mg salbutamol) < 0.70).
and follow-up through pulmono
onth.
written informed consent.
diagnosis.
nary vascular disease.
e of performing the study, an
spiratory function tests possiblbacterial infection data in these patients.2e5 Finally, there
is a group with characteristics shared with bronchial
asthma, which has generally been excluded from clinical
trials. However, certain studies suggest that these patients
constitute a particular phenotype whose evolution presents
differentiated characteristics related to a greater concen-
tration of eosinophils in the secretions and in the bronchial
mucose.6e10
Therefore, from the clinical point of view, it is possible
to identify 3 different COPD phenotypes, whose assessment
could help get a better understanding and management of
the disease.
The objective of this study is to determine the preva-
lence of each phenotype in a population of stable COPD
patients, and analyze the most relevant clinical charac-
teristics in each of them.
Methods
This is an epidemiologic, cross-sectional, observational,
and multicenter study performed in 40 pulmonology out-
patient services in Spain. There were no interferences on
the investigator’s decision about the health care or the
medical treatment that is most appropriate for the patient.
All the necessary data to assess the objectives anticipated
in the protocol were registered in a single visit. Each
investigator selected, in a consecutive manner, the first 5
COPD patients who met all inclusion criteria and none of
the exclusion ones, during a period of two months. Finally
344 COPD patients diagnosed according to GOLD criteria
with a significant smoking history (>10 pack years) were
recruited. 13 were excluded because they did not have
complete information, so that 331 were finally eligible for
the study (Table 1).I) is greater than 10.
se (COPD) according to GOLD 2007 criteria (post-bronchodi-
logy visits, both in hospitals and in other specialized health
y serious physical and/or mental impediment that would not
e.
726 J.L. Izquierdo-Alonso et al.The study was approved by the Clinical Research Ethics
Committee of the University General Hospital of Guadala-
jara (Spain), and all the patients were informed of the
characteristics and objectives of such study, giving their
written consent for their participation.
Data were collected by means of a standardized case
report form including demographic data, characteristics of
the chronic obstructive pulmonary disease, comorbidities,
and usage of health care resources. The impact of the
disease on the patients was analyzed with the following
questionnaires: LCADL (London Chest Activity of Daily Liv-
ing scale), SF12 and CCQ (Clinical COPD Questionnaire), all
of them validated to Spanish. The degree of dyspnea was
assessed using the Medical Research Council (MRC) vali-
dated scale. Table 2 describes the criteria used to assign
each patient to a certain phenotype.
Statistical analysis
A descriptive analysis was performed for all study variables,
presenting the absolute and relative frequencies in case of
qualitative variables, as well as the mean with standard
deviation in the case of the continuous variables.
In order to compare independent samples, Pearson’s chi-
square test was used to compare quantitative variables.
Alternatively for qualitative variables Fisher’s exact test for
2  2 tables (or the probability ratio in other tables, if
necessary) were used. For quantitative variables, the
ANOVA test, or its non-parametric equivalent H-Krus-
kaleWallis test, were used. For the analysis between
groups, the post-hoc MDS test was used for equal variances,
and the Tamhane’s T2 test was used for different variances.
In all the statistical tests performed, a level of statistical
significance below 0.05 was used. The SPSS version 17.0
statistical package was used.
Results
From 331 patients valid for the study the 43.2% (N Z 143)
presented an emphysematous phenotype (type 1), 44.7%Table 2 Definition of phenotypes.
Phenotype 1: EMPHYSEMA (at least one of the criteria)
1. Pulmonary emphysema proved by CT.
2. Diffusion test with TLCO/VA values inferior to 80% and thorax
described by Miniati et al.36e38
Phenotype 2: Chronic bronchitis.
1. Habitual coughing and expectoration (chronic bronchitis crite
2. Diffusion test with TLCO/VA values superior to 80%.
3. Absence of pulmonary emphysema demonstrated through ima
previous criteria.
4. Absence of asthma antecedents.
Phenotype 3: “COPD-asthma”
1. Diffusion test with TLCO/VA values superior to 80%.
2. Absence of pulmonary emphysema demonstrated through ima
previous criteria.
3. Personal history of asthma before the age of 40.6(N Z 148) were chronic bronchitic (type 2), and the other
12.1% showed a phenotype showing mixed characteristics
with asthma (type 3). There were no significant differences
in the level of smoking (PYI: 37.8 (11.8), 39.9 (10.3) and
35.6 (10.9)) respectively, in the gasometric values, or in the
disease’s evolution time among the three groups. Type 1
patients showed lower FEV1 values, 46.6% (21.1), 55.2%
(21.2), and 54.4% (21.8), respectively (p < 0.05) and
greater levels of dyspnea (p < 0.05) (Table 3).
No significant differences were observed in the per-
centage of patients who had had at least one exacerbation
in the last year (68.8%, 63.9%, 64.9%; p Z 0.25), in the
number of exacerbations (pZ 0.56), in the number of visits
to emergency room (total and due to COPD), or in the
number of hospital admissions (Table 4).
45.4% of the patients also suffered of arterial hyper-
tension (AHT), 34.0% presented dyslipidemia and 16.9%
diabetes. These prevalences were different in the different
groups. The subpopulation of patients with phenotype 2
had a greater prevalence of cardiovascular risk factors,
except in the case of smoking, where no statistically sig-
nificant differences were observed. 10.6% of the sample
had ischemic heart disease, especially in types 2 and 3
(5.3%, 13.5% and 15% respectively; p Z 0.08). Differences
were statistically significant for sleep apnea syndrome
(SAS) (4.9%, 23.6% and 12.5%, respectively; p < 0.001) but
not for arrhythmias (p Z 0.91), cerebrovascular disease
(p Z 0.77), peripheral vascular disease (p Z 0.20), and
cardiac failure (p Z 0.58) (Table 5).
Excluding short-acting bronchodilators, which were
mainly used as rescue medication, the COPD treatment
most frequently used was tiotropium (83.7%), followed by
the combination of long acting b-2 adrenergic agonists
(LABA), and inhaled corticoids (IC). By phenotype, the
frequency of patients with a fixed combination of LABA/IC
was significantly higher in the subpopulation of phenotype 3
patients (85% versus 69.9 and 64.2% for groups 1 and 2,
respectively; p < 0.05), while the medications of the car-
diovascular sphere, home ventilation (HF), and CPAP were
more frequently used in patients with chronic bronchitic
phenotype (Table 6).radiography suggesting emphysema, according to the criteria
ria).4
ging techniques, CT, or thorax radiography, according to the
ging techniques, CT, or thorax radiography, according to the
Table 3 Baseline characteristics among in the three COPD groups.
Group 1 Group 2 Group 3 p
Age (years) 66 (9) 69 (9) 64 (10) <0.05 (*, ***)
Sex (male %) 82.5 92.6 76.9 <0.05 (*, ***)
Packs/year 49 (23) 51 (25) 54 (32) 0.53
Active smoker (%) 29.8 24.8 28.9 0.63
Height (cm) 165 (7.7) 165 (8.2) 165 (7.4) 0.84
BMI (kg/m2) 25 (4) 30 (5) 28 (4) <0.001 (&)
FEV1 (% predicted) 46.6 (21) 55.2 (21) 54.4 (21.8) <0.05 (*)
FVC (% predicted) 72.8 (24) 71.3 (20) 73.2 (21) 0.85
FEV1/FVC 48 (14) 58 (11) 58 (10) <0.001 (*, **)
TLCO (%) 53 (24) 71 (21) 70 (20) <0.001 (*, **)
TLCO/VA (%) 60 (25) 84 (20) 85 (24) <0.001 (*, **)
PaO2 (mmHg) 66 (11) 64 (9) 69 (11) 0.27
PaCO2 (mmHg) 41 (6) 42 (7) 44 (5) 0.48
PH 7.42 (0.03) 7.42 (0.03) 7.42 (0.02) 0.95
Dyspnea (MRC)
I 7.0% 14.2% 22.5% <0.05 (*, **)
II 37.8% 48% 47.5%
III 32.1% 27.7% 27.5%
IV 18.9% 9.5% 2.5%
V 4.2% 0.7% 0
Time of disease evolution (years) 10.9 (8) 11.6 (9) 10 (8) 0.58
Education level (%)
Low 8.4 15.6 15
Primary 51.7 52.4 55
Secondary 29.4 21.8 10
University 10.5 10.2 20 0.07
Active working situation (%) 19.6 14.4 27.5 0.11
* Significant between 1 and 2; ** Significant between 1 and 3; *** Significant between 2 and 3.
& Significant between all the groups.
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tionnaire among the different COPD phenotypes. The
quality of life using the SF12 generic questionnaire showed
that physical health was significantly better in phenotype 3
patients, (p < 0.05). The London Chest Activity of Daily
Living (LCADL) scale showed that patients with type 1
phenotype showed a greater sensation of dyspnea while
performing everyday life activities (ADL), self-care, and
leisure (Table 7).
Discussion
The main conclusion of our work is that, for an equal degree
of smoking, three patients’ profiles adjusting to the threeTable 4 Exacerbation frequency according to COPD phenotype
Exacerbations in the last year.
Patients with any exacerbation in the last year (%).
Only one
Two or more
No. of visits to the emergency room in the last year due to COPD
Hospital admittances in the last year due to COPD exacerbation.
ICU admittances in the last year due to COPD exacerbation (% paclassic COPD phenotypes can be identified in clinical prac-
tice. Patients with presence of pulmonary emphysema show
lower BMI, worse pulmonary function, and greater degree
of dyspnea. The main characteristic of the group with
chronic bronchitis is that, this is the type of patients
showing a greater concentration of comorbidity, specially
associated to SAS, and cardiovascular risk factors. This
group presented a BMI significantly higher than the other
two. Therefore, obesity may constitute a bias explaining, at
least partially, the differences in other comorbidities.
Finally, group 3 is not large in a general population of COPD,
and it is characterized by a greater prevalence in women.
The prevalence in this group may vary notably when diag-
nostic criteria are modified.6.
Group 1 Group 2 Group 3 p
2.08 (1.38) 2.16 (1.30) 1.86 (1.21) 0.56
68.8% 63.9% 64.9% 0.25
44.8% 39.1% 50% 0.57
55.2% 60.9% 50%
. 1.73 (1.12) 1.76 (1.25) 1.69 (0.79) 0.43
1.32 (0.67) 1.32 (0.78) 1.33 (0.71) 0.82
tients). 1.4% 4.8% 2.6% 0.26
Table 5 Comorbidities in each COPD phenotype.
Group 1 Group 2 Group 3 p
Arterial hypertension (%) 32.6 60.8 33.3 <0.001 (*, ***)
Dyslipidemia (%) 28.6 41.4 25.6 <0.05 (*)
Diabetes (%) 12 23.4 10.3 <0.05 (*)
Cardiovascular disease (%) 6.3 13.5 15 0.08
Arrhythmia (%) 9.1 8.1 10 0.92
Cerebrovascular disease (%) 4.9 6.8 5.0 0.77
Peripheral vascular disease (%) 7.7 14.2 10 0.20
Cardiac insufficiency (%) 9.8 13.5 10 0.58
SAS (%) 4.9 23.6 12.5 <0.001 (*)
* Significant between 1 and 2; ** Significant between 1 and 3; *** Significant between 2 and 3.
& Significant between all the groups.
SAS: Sleep apnea syndrome.
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discrepancy of criteria within the scientific community, in
clinical practice it is identified as a characteristic of the
disease allowing establishing differences of clinical rele-
vance.11 This aspect is really important, since the evidence
collected during the last years confirms that, for the same
FEV1, COPD patients can be very different from the clinical,
functional, imaging techniques, and evolution course point
of view. The ECLIPSE study has recently demonstrated that
these differences also extend to exacerbations and FEV1
deterioration.12e15 From this point, approaches for pheno-
type identification in COPD have been very varied.16 In view
of the approach a priori identifying the most relevant
phenotypes, certain studies base their strategy in trying to
identify all the possible phenotype features and, subse-
quently, establish groups after performing statistical tests,
like factorial analyses and cluster studies.17e20 However,
even both approaches may be complementary, in theseTable 6 Main cardiorespiratory drugs prescribed in each group
Group 1
Ipratropium 6.3
LABA 36.4
Inhaled corticoid (IC) 28
Tiotropium 85,3
LABA/IC 69.9
Theophylline 18.2
OCD 23.8
HMV 0.7
CPAP 2.1
ACE inhibitors 16.8
ARB II 14.4
Antiaggregants 18.2
Statins 27.3
Treatment against smoking 18.9
LABA: Long acting beta agonists.
OCD: Chronic oxygen therapy.
HMV: Home mechanical ventilation.
ACE: Angiotensin converting enzyme.
ARB II: Angiotensin II receptor blockers.cases, most of the phenotype characteristics lack of clinical
meaning, in other cases their relevance has not been
established and, frequently, they reflect changes asso-
ciated to different stages of the disease, instead of dif-
ferent profiles of patients. On the contrary, the advantage
of using COPD predefined phenotypes is that they are easy
to apply in clinical practice, their theory basis is solid, they
represent groups of patients with clinical characteristics
differentiated regardless functional stage and, frequently,
they condition the functional evolution or exacerbation’s
characteristics.7,8,21
In a study, Garcı´a-Aymerich et al.17 analyzed a cohort of
342 patients who were hospitalized for the first time due to
COPD exacerbation in 9 Spanish tertiary hospitals. By means
of a cluster analysis, they identified three types of patients:
group 1 presented a greater functional severity and a worse
clinical situation, from the respiratory point of view; group 2
presented less functional deterioration, and group 3was also.
Group 2 Group 3 p
6.1 7.5 0.95
33.1 17.5 0.07
26.4 15 0.24
83.8 77.5 0.49
64.2 85 <0.05
12.8 5 0.088
16.9 10 0.09
6.1 5 <0.05
13.5 7.5 <0.001
35.1 22.5 <0.001
25 7.5 <0.01
25 17.5 0.30
34.5 25 0.30
10.1 12.5 0.09
Table 7 Quality of life using the SF12 generic questionnaire, London Chest ADL and CCQ.
Group 1 Group 2 Group 3 p
London Chest ADL
Self-care 6.53 (2.88) 6.01 (2.87) 5.00(1.99) <0.01 (**, ***)
Domestic 5.98 (7.03) 4.87 (5.07) 5.62 (5.04) 0.55
Physical 4.50 (1.49) 4.26 (1.52) 3.92 (1.35) 0.07
Leisure 4.19 (1.70) 3.86 (1.31) 3.62 (1.31) <0.05 (**)
SF 12
Physical 37.09 (9.73) 39.54 (10.66) 42.92 (9.46) <0.05 (*, **)
Mental 49.4 (11.29) 50.9 (10.65) 51.63 (9.78) 0.40
CCQ 2.19 (1.20) 2.12 (1.11) 1.94 (1.13) 0.47
* Significant between 1 and 2; ** Significant between 1 and 3; *** Significant between 2 and 3.
& Significant between all the groups.
Clinical characteristics in COPD phenotypes 729characterized by a lower functional deterioration but
a greater obesity prevalence, cardiovascular disorders, dia-
betes, and systemic inflammation. In a certain way, these
data are consistent with our results, which also identify, for
an equal degree of smoking, a group of patients with greater
comorbidity in the cardiovascular sphere and another more
symptomatic group with characteristics of emphysema. Due
to selection criteria in Garcı´a-Aymerich’s study the group
sharing certain common characteristics with asthma could
be excluded at entry. Another difference of this study is that
our patientswere randomly selected fromagroupof patients
visited in external visits. Therefore, these data could be
extrapolated to COPD general population assisted in an
outpatient environment.
In our study, in order to approach COPD heterogenicity,
classic concepts were recovered. Despite their relevance,
such concepts were abandoned in the last years, especially
since the publication of the GOLD guidelines. During the
decades previous to the COPD approach, 2 universal phe-
notypes were used: type A (pulmonary emphysema), and
type B (chronic bronchitis). They reflected the two main
clinical profiles also based on peculiar features at the
image, functional and pathologic level. Subsequently, cer-
tain authors considered that this classification was obsolete
and was of poor clinical usefulness, promoting a uniform
vision of COPD whose classification was based in FEV1
values. The result was that, after the publication of the
Global Initiative for Obstructive Lung Diseases (GOLD) in
2001, key aspects in relation with the disease’s hetero-
genicity have been deleted, giving priority to the simplicity
of spirometric values. This way of understanding COPD may
have been useful in a certain moment in order to transfer
simple messages to big populations, but it currently poses
a barrier for progressing in dealing with this disease.
New assessment methods have been incorporated in the
risks control, but clinical experience suggests that we must
keep on progressing in the characterization of patients’
profiles, since various aspects related to the risk, such as
comorbidity or exacerbations, may be conditioned by the
patient’s profile. Although a degree of overlapping of the
different lesions in airways and pulmonary parenchyma is
high, it is clear that the presence of different injuries in the
airways and pulmonary parenchyma, and the differences
observed from the clinical point of view, make it reason-
able to recover this approach, although it may be necessaryto subsequently validate their real utility in longitudinal
studies.22,23 In fact, this relevance was already observed in
classical studies.24 The information obtained in the last
years, which goes from basic aspects to the positioning of
certain drugs in the treatment of these patients, invites us
to reassess the classic phenotypes.25e29
Surprisingly, despite the evident differences in clinical
characteristics of patients, the amount of exacerbation was
similar in the three groups. However, the simple numeric
assessment of exacerbations has a limited value, since
there are important limitations in the current definition of
COPD exacerbation.30 The present study does not allow for
the identification of characteristics of all exacerbations,
but this should be a primary objective in any study with
a longitudinal design, also including the possible role of
cardiovascular disorders and other diseases associated in
the deterioration of patients and the hospital
admittances.31e33 On the other hand, since they are pa-
tients with a complete treatment for their disease, it can-
not be excluded that the absence of differences in this
section may be, at least, conditioned by a greater effi-
ciency of the treatment in those patients with a greater risk
of exacerbations. Although there are data in the literature
relating the presence of chronic bronchitis with a greater
risk of exacerbations,34 our data belonging to a treated
population, do not allow for an adequate assignation of the
type of patient by their exacerbations’ history. In fact,
a greater risk of exacerbations has been described when
there exists a greater amount of emphysema, when chronic
bronchitis is associated, and when common characteristics
with asthma exist.5,6,35 These findings invite us to pose
different phenotypes of exacerbations, whose treatment
and prevention should be individualized according to
baseline characteristics of each patient.7,8,17 Only a con-
trolled study previously analyzing the patients’ profiles
could give us an answer to this question.
The prescription pattern observed is not surprising, since
the current clinical guidelines recommend that the phar-
macological treatment should be based mainly on FEV1
values and on the symptoms. The recent experience in the
development of roflumilast indicates that such approach
may not be correct, since the previous identification of
patients’ profiles allows achieving a greater benefit when
the drug is administered to the most adequate patient, and
when its use is prevented in those patients who are unlikely
730 J.L. Izquierdo-Alonso et al.to benefit from it.25,26 This approach is equally valid for
drugs such as inhaled corticoids and can be key in the
development of new drugs whose efficacy in certain groups
of patients may be concealed when a general COPD popu-
lation is analyzed.
The impact on life quality is difficult to assess in a cross-
sectional study like ours, where most of the patients are
receiving a great number of drugs. However, the different
clinical expression observed in each group is reflected, both
in the LCADL and in the SF12, with predominant variables,
mainly respiratory (dyspnea, etc.), in patients with a pre-
dominance of emphysema characteristics.
The main limitation of our work is that it is a cross-
sectional study. Therefore, clinical relevance of these data
should be prospectively assessed in a longitudinal study.
Another limitation is that the population selected comes
from patients visiting the pulmonology outpatient services,
therefore the results are not necessarily likely to be
extrapolated to general population. Finally, the criteria
established to define the groups may seem arbitrary, but
the differentiation of COPD-asthma phenotype is similar to
that used in the COPDgene study.6 Likewise, the criteria to
differentiate the group with a predominance of chronic
bronchitis and the group with emphysema, although they
do not allow the establishment of strict cut-off points, they
do allow to refine patients’ profiles where one of these
components is predominant.
Conclusions
In a general population of COPD patients, most of them
adapt to chronic bronchitis and emphysema phenotype.
Emphysematous patients normally show a worse pulmonary
function and a greater dyspnea, although there were no
differences in the use of hospital health care resources.
The greater comorbidity in group 2 patients may require
specific strategies in this subgroup of patients. These data
support the abandonment of a homogeneous handling of
COPD patients, and they invite us to develop clinical and
investigation strategies based on patients’ profiles.
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